Rituximab for Bone Lymphoma
Authors: David G. Savage, Ronald Staron
Journal: Annals of Internal Medicine (2001)

Letters19 June 2001Rituximab for Bone LymphomaDavid G. Savage, MD and Ronald Staron, MDDavid G. Savage, MDColumbia University; New York, NY 10032 (Savage, Staron)Search for more papers by this author and Ronald Staron, MDColumbia University; New York, NY 10032 (Savage, Staron)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-12-200106190-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Diffuse, large B-cell non-Hodgkin lymphoma is the most common osseous lymphoma (1). Although most patients respond to chemotherapy and radiation therapy, 10% to 15% have aggressive, resistant disease (2).A 58-year-old woman presented in June 1997 with painful destructive lesions in the 12th thoracic and 4th lumbar vertebrae. Biopsy revealed diffuse, large B-cell non-Hodgkin lymphoma. She received a radiation dose of 4000 cGy to the T11–L5 spine, followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone. In November 1997, she developed pelvic and midthoracic pain and a 5-cm parietal mass. Spinal magnetic resonance imaging revealed a ...References1. Ostrowski ML, Unni KK, Banks PM, Shives TC, Evans RG, O'Connell MJ, et al . Malignant lymphoma of bone. Cancer. 1986;58:2646-55. [PMID: 3779614] CrossrefMedlineGoogle Scholar2. Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H, et al . Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999;45:1213-8. [PMID: 10613315] CrossrefMedlineGoogle Scholar3. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al . Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-32. [PMID: 9731049] MedlineGoogle Scholar4. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al . IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-95. [PMID: 9310469] CrossrefMedlineGoogle Scholar5. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al . Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-76. [PMID: 10458242] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Columbia University; New York, NY 10032 (Savage, Staron) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDramatical improvement of chemoresistant bone lymphoma with rituximabPrimary bone lymphomaRituximabRituximab Provides Durable Remission in a Patient with Refractory Aggressive Diffuse B-cell Lymphoma Failing Salvage Chemotherapy 19 June 2001Volume 134, Issue 12Page: 1156-1157KeywordsB cellsBoneChemotherapyDiffuse large B-cell lymphomaLesionsLymphomaSpinal cordSpineToxicityVertebrae ePublished: 19 June 2001 Issue Published: 19 June 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...